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Genetically determined higher levels of angiotensin-converting 
enzyme (ACE), which do not significantly affect blood pressure 
or angiotensin II and aldosterone levels (1), have been correlated 
in several studies with an increased risk of a broad and overlap-
ping constellation of diseases, including diabetic nephropathy (2), 
breast cancer (3), Alzheimer disease (4), Parkinson disease (5), con-
gestive heart failure (6), myocardial infarction (7), and stroke (8). 
In the reverse direction, inhibitors of the enzyme (ACEIs) have ben-
eficial effects beyond those attributable to changes in blood pres-
sure in conditions such as diabetic nephropathy (9) and coronary 
artery disease (10). ACEIs have also been reported to have benefi-
cial effects on the incidence of cancer (11) and Alzheimer disease 
(12). Thus, higher levels of ACE lead to an increased risk of devel-
oping many diseases that are also associated with senescence.
Some of the detrimental effects of higher ACE levels that have 
been observed in humans have been demonstrated in animal 
models. Thus, in agreement with the human data, mice with 1, 
2, or 3 copies of the Ace gene and proportional plasma ACE levels 
have indistinguishable blood pressures and similar angiotensin II 
levels. Yet, when these mice are made diabetic with streptozotocin 
(STZ), the animals with 3 Ace genes develop markedly worse kid-
ney function, as judged by higher urinary albumin excretion, than 
the animals with 1 or 2 Ace genes (13). This observation, com-
bined with prior experimental findings (14) and computer simu-
lations (15) showing that modest changes in ACE levels affect the 
levels of its substrates much more than its products, led to the 
inference that the ACE substrate bradykinin is the likely mediator 
of the kidney effects.
Recently this inference received support from a demonstration 
that, by age 6 months, mice that are diabetic because of a domi-
nant mutation (Akita) in the Ins2 gene and also lack the brady-
kinin B2 receptor develop more severe kidney pathology than 
their diabetic littermates having the B2 receptor. Thus, the double 
mutants have a substantial degree of mesangial sclerosis in many 
renal glomeruli and exhibit overt albuminuria (equivalent to >550 
mg/d in humans) compared with a minor degree of mesangial scle-
rosis in some glomeruli and microalbuminuria (equivalent to <150 
mg/d) in their simply Akita diabetic littermates (16). Surprisingly, 
as we now report, this combination of diabetes and absence of the 
bradykinin B2 receptor leads to a more general problem clearly 
detectable by 12 months of age: namely, the Akita diabetic mice 
that also lack the B2 receptor show enhancement of a variety of 
indicators of accelerated senescence that we find is already a fea-
ture of untreated Akita diabetic mice and (to a lesser extent) of B2 
receptor–null mice.
Results
External indices of senescence. The first sign of accelerated senescence 
that we observed in our mice is illustrated in Figure 1A. By 12 
months of age, mice heterozygous for the dominant Akita diabe-
togenic mutation in the insulin 2 gene (Ins2Akita/+) and homozygous 
for a null mutation in the bradykinin B2 receptor gene (Bdkrb2–/–) 
showed considerable alopecia. Hair loss was rare in the singly mutant 
(Akita diabetic or B2 receptor–null) and nonmutant WT mice at this 
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age (Figure 1A). The loss of hair in the double mutants was due to 
a reduction in the number of hair follicles and was accompanied by 
marked thinning of the dermis (Figure 1B). Both types of diabetic 
mice (singly mutant Akita and doubly mutant Akita B2 receptor–
null) had essentially no subcutaneous fat, although subcutaneous 
fat was normal in the 12-month-old nondiabetic mice (B2 receptor–
null and WT). The lifespans of the mice were progressively shorter 
(Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI26958DS1) in the order WT > B2 
receptor–null > Akita diabetic > Akita diabetic B2 receptor–null 
(909 ± 45 days, 755 ± 23 days, 373 ± 30 days, and 246 ± 25 days, 
respectively), and the effects on the lifespans of diabetic and B2 recep-
tor–null mice were highly significant (P < 0.0001 and P < 0.0001, 
respectively, by 2-factor ANOVA). Diabetes and absence of the B2 
receptor, when combined, led to the shortest lifespan (P < 0.01 for 
double mutant versus all other groups, by Tukey-Kramer honestly 
significant difference [HSD]) but showed no evidence of interaction 
(P of interaction = 0.65 by 2-factor ANOVA).
The double mutants also exhibited marked kyphosis (Figure 1A), 
present to a lesser degree in singly mutant Akita diabetic animals 
but rare in B2 receptor–null mice and absent in WT mice at this 
age. Kyphosis is often a manifestation of osteoporosis, and Figure 
1C shows that femur mineral bone density decreased progressively 
again in the order WT > B2 receptor–null > Akita diabetic > Akita 
diabetic B2 receptor–null. Diabetes and absence of the B2 receptor 
each affected bone density (P < 0.0001 and P < 0.01, respectively; 
Supplemental Table 4)	and, when combined, added to the sever-
ity of this phenotype but showed no evidence of interaction (P of 
interaction = 0.2). The doubly mutant mice had the most severe 
kyphosis and the greatest reduction in bone density (P < 0.05 ver-
sus other groups, by Tukey-Kramer HSD).
Cellular indices of senescence/apoptosis. These external signs of accel-
erated senescence prompted us to look at other indicators of aging 
in the 4 types of mice, including decreases in spermatogenesis. Fig-
ure 2A shows that all spermatic cords appeared normal in the WT 
and B2 receptor–null animals at 12 months of age. A loss of sper-
matogenesis was visible in some cords (outside the dotted red line) 
in the Akita diabetic animals. Atrophic changes were severe in the 
double mutants (Akita diabetic B2 receptor–null).
We also observed numerous vacuoles containing intracellular 
accumulations of brown pigmented material in the testicular Ley-
dig cells of the Akita diabetic B2 receptor–null mice (Figure 2B). 
They were present to a somewhat lesser degree in the simply diabet-
ic animals, were much fewer in the B2 receptor–null mice, and were 
absent in the WT mice. This same type of material accumulated in 
the renal proximal tubule cells (Figure 3A) of the Akita diabetic B2 
receptor–null mice, and to a lesser degree in the simply diabetic 
animals; it was virtually absent in nondiabetic animals lacking 
the B2 receptor and in the WT mice. Electron microscopy of the 
renal proximal tubule cells showed that they contained phagoly-
sosomes with laminated lipid debris consistent with their being 
autophagolysosomes (Figure 3B). Intracellular accumulations in 
autophagolysosomes of lipid and protein debris, including lipo-
fuscin, are known indicators of cellular senescence (17), oxidative 
stress, and increased mitochondrial turnover (18). Finding these 
deposits suggests that mitochondrial damage plays an important 
role in the graded deterioration of renal function described previ-
ously in 6-month-old Akita diabetic and doubly mutant mice (16), 
and in the graded loss of testicular function described here in the 
12-month-old mice (Figure 2A).
A senescence-associated phenotype associated with increased 
apoptosis, particularly in cells with a rapid cellular turnover, 
Figure 1
Appearance and associated indicators of senescence in mice at age 12 months. (A) General appearance of male mice with the following geno-
types: WT at both the insulin 2 and the bradykinin B2 receptor loci, homozygous null for the B2 receptor (Bdkrb2–/–), heterozygous Akita for insulin 2 
(Ins2Akita/+), and doubly mutant (Bdkrb2–/–Ins2Akita/+). Kyphosis was moderate in the Akita diabetic mouse; it was severe in the doubly mutant animal, 
which also exhibited marked alopecia. The animals imaged were among the most severely affected of each genotype. (B) H&E-stained abdominal 
skin of mice with the same 4 genotypes. Scale bars: 1 mm. Subcutaneous fat (asterisks) was present in both nondiabetic animals but was absent 
in the diabetic animals. The skin of the double mutant was thin and had few hair follicles. The areas selected for imaging are representative of each 
genotype. (C) Bone mineral density of femurs of mice of the 4 genotypes, assessed with dual-emission x-ray absorptiometry. Data are presented 
as means ± SEM with the numbers of animals shown in white digits (see Supplemental Table 4 for 2-factor ANOVA analysis).
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has recently been described in mice carrying a mutator allele of 
mitochondrial DNA polymerase γ (19), and in mice with short 
telomeres (20). We therefore asked whether the pathological dif-
ferences observed in the testes (Figure 2) and kidneys (Figure 3) 
of our 12-month-old mice were paralleled by differences in the 
extent of apoptosis in these same tissues, as assayed by TUNEL 
staining. We found that the degree of apoptosis approximately 
paralleled the observed gradation in loss of spermatogenesis in 
the 4 types of mice. Diabetes and absence of the B2 receptor both 
had highly significant and strongly interacting effects on the fre-
quency of the apoptotic cells in the seminiferous tubules, the cells 
of which had rapid turnover (Supplemental Figure 2, A and B, and 
Supplemental Table 4). We also observed a very similar gradation 
in the frequency of apoptotic cells in intestinal villi, another site 
of rapid cellular turnover (Supplemental Figure 3, A and B, and 
Supplemental Table 4).
Senescence-associated gene expression in vivo. Aging is accompanied by 
changes in gene expression. For example, the expression of TGF-β1 
and of connective tissue growth factor (CTGF) is enhanced in old 
animals and in late passages of cultured cells (21). Increases in the 
expression of these apoptosis-related genes (22, 23) has also been 
implicated in changes that accompany fibrogenesis in diabetes 
(24). Similarly, increased expression of the apoptosis-related genes 
p53 (23), forkhead box O1 (FoxO1) (25), and α-synuclein (26) has 
been reported in senescent cells and/or animals (21, 27, 28). Table 
1 shows that the expression of all these genes was increased relative 
to WT in the kidneys of the B2 receptor–null animals (6% to 47% 
greater than WT), even more in the Akita diabetic animals (57% to 
114%), and still more in the double mutants (128% to 325%). The 
effects of diabetes on expression (P < 0.0001 for all the genes; Sup-
plemental Table 4) and of absence of the B2 receptor on expression 
(P < 0.05 for all the genes except CTGF, P = 0.06; Supplemental 
Table 4) were both significant with no evidence of interaction, and 
the double mutant was significantly more affected than any of the 
others (P < 0.05 versus other groups).
Figure 2
Testes of 12-month-old mice of the 4 genotypes. (A) Low-magnifica-
tion H&E-stained testes. Loss of spermatogonia was severe in the dou-
ble mutant. Some spermatic cords in the Akita diabetic mouse were 
aspermic (outside the dotted red line). The testes of the B2 recep-
tor–null and WT mice had normal spermatic cords. (B) High-magnifi-
cation H&E-stained testes of 12-month-old mice. There were numer-
ous intracellular pigmented vacuoles in the Leydig cells of the doubly 
mutant mouse. Pigmented vacuoles in Leydig cells were also present 
to a somewhat lesser degree in the Akita diabetic mouse. They were 
sparse in the B2-null mouse, and absent in the WT mouse. The areas 
selected for imaging in A and B are representative of each genotype. 
Scale bars: 100 μm (A), 10 μm (B).
Figure 3
Kidneys of 12-month-old mice of the 4 gen-
otypes. (A) PAS-stained kidneys. There 
were numerous intracellular pigmented 
vacuoles in the cytoplasm of the proximal 
tubular epithelial cells of the doubly mutant 
mouse. Pigmented vacuoles were present 
to a lesser degree in the proximal tubules 
of the Akita diabetic mouse with intact B2 
receptors but were absent in the B2 recep-
tor–null and WT nondiabetic mice. The 
areas selected for imaging are represen-
tative of each genotype. (B) Transmission 
electron micrograph of a renal proximal 
tubule cell from a doubly mutant mouse. 
Note the numerous lipid debris–contain-
ing phagolysosomes with focal laminations 
(arrows). Scale bars: 10 μm (A), 1 μm (B).
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Oxidative stress in vivo. These several observations show that 
absence of the bradykinin B2 receptor increases the severity of a 
variety of senescence-associated changes that occur in untreated 
diabetic mice. The changes in kidney proximal tubule cells and the 
Leydig cells of the testis illustrated above are particularly informa-
tive. These 2 cell types both have high metabolic activity as judged 
by their mitochondrial content. They are consequently likely to be 
particularly vulnerable to disturbances	in mitochondrial function 
and to oxidative stress. We therefore determined in our animals 
the level of thiobarbituric acid–reactive substances (TBARSs) in 
plasma and of reduced glutathione (γ-glutamylcysteinylglycine; 
GSH) in erythrocytes, 2 reciprocal indicators of oxidative stress. 
The resulting data (Figure 4, A and B) show that the TBARS levels 
increased and the GSH levels decreased in the same progression as 
in the senescence-associated phenotypes. The effects of diabetes 
and of absence of the B2 receptor on TBARSs and GSH were both 
highly significant (P < 0.001; Supplemental Table 4), with no evi-
dence of interaction (P > 0.05).
Mitochondrial DNA damage in vivo. Damage to mitochondrial 
DNA (mtDNA), including an increased content of 8-hydroxy-2′-
deoxyguanosine (8-OHdG) and increased frequencies of point 
mutations and deletions, is a known consequence of oxidative 
stress, and it increases with age (29–31). Accordingly, we deter-
mined the extent of damage to mtDNA in our mice. Figure 5 (A, B, 
and C) shows that the incidence of these several indicators of DNA 
damage and senescence increased progressively in kidney mtDNA, 
from WT mice to B2 receptor–null mice to Akita diabetic mice to 
Akita diabetic B2 receptor–null mice. The effects of diabetes on all 
these indicators of DNA damage (P < 0.0001; Supplemental Table 
4) and of absence of the B2 receptor (P < 0.05) were both signifi-
cant by 2-factor ANOVA with no evidence of interaction, except for 
8-OHdG (P < 0.001). Approximately 65% of the point mutations in 
all groups were A:T to G:C transitions	(data not shown). A similar 
distribution of point mutations in association with aging has been 
reported previously (19, 32).
Oxidative stress in vitro. The bradykinin B2 receptor acts in part via 
its downstream influence on NO formation. We therefore carried 
out in vitro experiments to determine the effects of bradykinin (BK) 
on oxidative stress induced by high glucose, and to determine the 
effects on the induced oxidative stress of inhibiting NO produc-
tion. In these experiments we used EA.hy926 vascular endothelial 
cells (33) and a fluorochrome that localizes in mitochondria and 
fluoresces when oxidized. Figure 6 (A and B) shows that the 
fluorescence of the endothelial cells cultured in a high-glu-
cose (HG) medium, containing glucose at the same concen-
tration at which it occurs in the plasma of our diabetic mice, 
750 mg/dl, increased significantly relative to the fluorescence 
of cells cultured at a normal glucose (NG) concentration, 100 
mg/dl (P < 0.01, by Tukey-Kramer HSD after 1-way ANOVA), 
indicating that HG increases mitochondrial oxidative stress. 
Addition of BK to the HG medium drastically decreased 
the fluorescence (P < 0.0001), indicating that BK markedly 
decreases this oxidative stress. The fluorescence returned 
almost to that seen with HG alone when Nω-nitro-l-arginine 
methyl ester	(l-NAME), an inhibitor of the NO synthases, was 
added to the HG plus BK medium (P > 0.05), indicating that 
the ameliorating effect of BK is mediated largely by NO.
Discussion
Diabetes mellitus in humans is the leading cause of end-
stage renal disease (34), and increased urinary albumin excretion 
is a well-established predictor of its development. Urinary albu-
min also increases in nondiabetic subjects with aging (35). Dia-
betes mellitus is a risk factor for many other conditions that also 
increase in frequency in nondiabetic individuals as they age. It is a 
risk factor for myocardial infarction (relative risk, 6.9) (36), dilat-
ed cardiomyopathy (relative risk, 3.0) (37), sudden cardiac death 
(relative risk, 4.0) (38), stroke (relative risk, 5.8) (39), Alzheimer 
disease (relative risk, 1.9) (40), and bone fractures (relative risk, 
1.3) (41). It is a risk factor for cancer of the liver (relative risk, 
2.2) (37), stomach (relative risk, 2.3) (42), colorectum (relative 
risk, 3.2) (37), pancreas (relative risk, 1.5) (37), bladder (relative 
risk, 1.4) (37), cervix (relative risk, 1.6) (42), breast (relative risk, 
1.3) (37), and endometrium (relative risk, 2.7) (42). Aging and 
diabetes are also independent risk factors for retinal macular 
degeneration (43) and distal polyneuropathy (44). Thus, diabetes 
mellitus affects the risk of developing many conditions that are 
associated with senescence.
The experimental data that we have presented demonstrate 
that, in 12-month-old mice, absence of the bradykinin B2 recep-
tor combined with diabetes due to the Akita mutation markedly 
Table 1
mRNAs in the kidneys of 4 types of animals at age 12 months
	 WT	 Bdkrb2–/–	 Ins2Akita/+	 Bdkrb2–/–Ins2Akita/+
TGF-β1 16.6 ± 4.4 18.7 ± 4.4 39.9 ± 3.3A 58.1 ± 3.6A,B
 (100 ± 27) (113 ± 27) (240 ± 20) (350 ± 22)
CTGF 45.9 ± 8.4 48.4 ± 8.4 78.8 ± 6.3A 106.7 ± 6.8A,B
 (100 ± 18) (105 ± 18) (172 ± 14) (233 ± 15)
p53 (100 ± 19) (141 ± 19)A (175 ± 14)A (242 ± 17)A,B
α-Synuclein (100 ± 46) (147 ± 46)A (266 ± 35)A (425 ± 41)A,B
FoxO1 (100 ± 21) (131 ± 21)A (178 ± 16)A (257 ± 19)A,B
Means ± SEM are shown for assays with 4–7 animals of each genotype. Data 
for TGF-β1 and CTGF are presented as picograms specific mRNA per micro-
gram total RNA, with percentage of WT in parentheses. Data for the other 
genes are relative to expression of β-actin and are presented in parentheses as 
percentage of WT. AP < 0.05 versus WT, BP < 0.05 versus Ins2Akita/+, by Tukey-
Kramer HSD (see Supplemental Table 4 for 2-factor ANOVA analyses).
Figure 4
Indices of oxidative stress in 12-month-old mice of the 4 genotypes. (A) 
Plasma levels of TBARSs. (B) Concentration of reduced glutathione 
(GSH) in erythrocytes. Data are presented as means ± SEM with the 
numbers of animals shown in white digits (see Supplemental Table 4 
for 2-factor ANOVA analysis).
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increases the severity of a wide range of senescence-associated phe-
notypic abnormalities that occur to a lesser degree in mice that are 
simply Akita diabetic. Although the extent of senescence-associ-
ated phenotypes in the simply Akita diabetic mice is much less 
than in the double mutants, it is nevertheless more severe than 
that normally seen in most human insulin-dependent diabetics 
in advanced societies. This is not unexpected, because the severe 
diabetes of the Akita mice is not treated, and because the mice are 
inbred. In contrast, insulin-dependent human diabetics are treated 
with insulin in developed countries and have much better genetic 
backgrounds (they are not inbred). Some comment is also required 
on our choice of the dominant Akita mutation to induce diabetes, 
rather than induction by STZ treatment. One reason is that the 
Akita-induced diabetes has a better-defined etiology (endoplasmic 
reticulum stress and proteotoxicity in the pancreatic β cells) than 
the diabetes due to STZ, and another reason is that the diabetes 
does not regress. Additionally, the genetic model gives several-
fold tighter data than the chemical model, and the nephropathy 
that develops in the Akita diabetic mice is more like that seen in 
human diabetics than is the nephropathy that develops in mice 
with chemically induced diabetes (45). Consequently, our present 
findings regarding the factors responsible for the development of 
senescence-related phenotypes in diabetic mice, and their enhance-
ment by absence of the bradykinin B2 receptor, bear strongly on 
the complications of diabetes in humans and their similarities to 
the effects of age in nondiabetic individuals.
For more than 50 years	it has been proposed that free radicals 
generated during normal or abnormal oxidative metabolism can 
cause sufficient cumulative damage to cells to lead to aging (46); 
and it has recently been shown that mitochondrial overproduction 
of superoxide activates major pathways of hyperglycemia-induced 
cellular damage (47). In our mice we find that the incidence of 
overt signs of senescence (alopecia, skin atrophy, kyphosis, osteo-
porosis, autophagosomic inclusions in renal tubule cells and tes-
ticular Leydig cells, testicular atrophy) and the incidence of chang-
es in the expression of genes implicated in aging (TGF-β1, CTGF, 
p53, FoxO1, and α-synuclein) increase in parallel with increases 
in ROS (plasma TBARSs) and reciprocal decreases in reductive 
species (erythrocyte GSH). The content of 8-OHdG in mtDNA 
increases in the same progression as the metabolic indicators of 
oxidative stress and the senescence-related phenotypes, as does the 
frequency of point mutations. However, we find that the majority 
Figure 5
Alterations in mtDNA in 12-month-old mice of the 4 genotypes. (A) 8-OHdG content in renal cortical mtDNA. (B) Frequencies of point mutations 
in the cytochrome b gene in the mtDNA used in A. (C) Relative proportion of D-17 deletions (as percentage of WT) in the same DNA, determined 
by quantitative PCR. Data are presented as means ± SEM with the numbers of animals shown in white digits (see Supplemental Table 4 for 
2-factor ANOVA analysis).
Figure 6
Oxidative stress in vitro. (A) Mitochondrial 
oxidation (assessed by MitoTracker Red 
CM-H2XRos fluorescence) in EA.hy926 
vascular endothelial cells cultured in the 
presence of normal glucose (NG), high 
glucose (HG), HG plus 1 μM bradykinin 
(BK), or HG plus BK plus 1 mM l-NAME. 
BK reduced the oxidative signal seen in 
HG; this reduction was largely abolished 
by the NOS inhibitor l-NAME. Scale bars: 
100 μm. (B) Quantitative analysis of Mito-
Tracker Red fluorescence from single cells 
under the 4 culture conditions used in A. 
The data are means ± SEM with the num-
bers of cells shown in white digits.
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of the additional point mutations are transitions, as also reported 
by others in aging mice (19, 32), whereas 8-OHdG leads mainly to 
transversions (48). We conclude that, although the increased level 
of 8-OHdG is a well-known indicator of oxidative stress, the point 
mutations we observe are unlikely to be a direct consequence of 
this modified base. However, we cannot exclude the possibility that 
the approximately 10-fold increase in the level of 8-OHdG over the 
WT level in the mtDNA of our double mutants affects their senes-
cence-associated phenotype, even though premature aging was not 
reported in mice with an approximately 3-fold increase in the level 
of mitochondrial 8-OHdG over the WT level, caused by heterozy-
gosity for disruption of the Sod2 gene (49).
Two recent reports (19, 50) are relevant to our present work. 
Both report that mice with a defective proofreading function in 
their mitochondrial DNA polymerase γ develop senescence-associ-
ated phenotypes similar to those that we observe (including alo-
pecia, kyphosis, osteoporosis, and reduced fertility). The mutants 
have an increased frequency of mutations in their mtDNA and an 
increased induction of apoptotic markers, particularly in tissues 
characterized by rapid cellular turnover, but do not have increased 
oxidative stress (19). However, this result does not exclude the 
possibility that chronic and severe oxidative stress can also lead to 
mitochondrial damage — including mutations like those reported 
in the polymerase γ mutants — that is sufficient to induce apop-
tosis in susceptible tissues. Thus, diabetes and absence of the B2 
receptor independently and largely additively increase oxidative 
stress in our mice. Diabetes and absence of the B2 receptor inde-
pendently — and even more in combination — increase the presence 
of mitochondrial debris in testicular Leydig cells and renal tubule 
cells. And diabetes and absence of the B2 receptor each increase the 
number of apoptotic cells in testicular seminiferous tubules and 
in intestinal villi of our mice, with the combined effects of the 2 
factors being significantly greater than the sum of their individual 
effects (P of interaction < 0.01). We infer from these observations 
that the graded oxidative stress in our mutant mice increases mito-
chondrial damage, readily detectable in metabolically active cells, 
and that this damage can reach a level sufficient to induce apop-
tosis in some actively dividing cells.
The experiments with endothelial cells that we have described 
here establish a connection among oxidative stress, diabetes, BK, 
and NO. High glucose induces an increase in oxidative stress in 
these cells that is inhibited by BK largely by an NO pathway. Exper-
iments by others (51) have shown that oxidative stress induced by 
high glucose in cultured endothelial cells is ameliorated by an ACE 
inhibitor, and that this amelioration is blocked by a B2 receptor 
antagonist, but not by a B1 receptor antagonist. Thus the in vitro 
ameliorating effects on oxidative stress of BK and of ACE inhibi-
tors are mediated at least in part through a common pathway that 
includes the bradykinin B2 receptor and probably NO.
A further clue to the possible chain of events leading to our 
results is provided by studies showing that endogenously pro-
duced NO regulated by Ca++ influx and acting through cytochrome 
oxidase, the enzyme responsible for approximately 90% of oxygen 
consumption, is probably responsible for the physiological regu-
lation of respiration in endothelial and other cells (51, 52); when 
oxygen tension is low, NO inhibits aerobic metabolism. NO regu-
lates cardiac oxygen consumption through a bradykinin-receptor 
mechanism, and this physiological mechanism is absent in B2 
receptor–null mice (53). Endothelial NOS plays an essential role 
in the regulation of renal oxygen consumption by NO (54), and 
NO (after inhibiting cytochrome oxidase) switches on glycolysis 
by activating the master regulator of glycolysis, PFK1 (55). Accord-
ingly, we suggest that a decrease in intracellular NO, caused either 
by reduced BK levels or by absence of the bradykinin B2 receptor 
(56), may impair this check on aerobic metabolism, with a conse-
quent increase in ROS and oxidative stress. Even in the absence of 
diabetes, BK is important in the context of accelerated senescence, 
as indicated in Supplemental Figure 4, which	shows that if mice 
lack the B2 receptor they develop alopecia and kyphosis by 2 years 
of age comparable to that seen in the B2-null Akita diabetic mice 
at 1 year of age, and not seen in WT mice of the same age. This is 
consistent with a report showing aging phenotypes in the hearts 
of mice lacking the B2 receptor (57).
In summary, we have demonstrated that absence of the bradyki-
nin B2 receptor increases the incidence of many detrimental factors 
also apparent in untreated Akita diabetic mice, including oxidative 
stress, 8-OHdG content, mutations in mtDNA, mitochondrial turn-
over, the expression of several senescence/apoptosis–related genes, 
and the occurrence of apoptosis in testicular seminiferous tubules 
and intestinal villi. Together these increases caused by absence of 
the bradykinin B2 receptor culminate in a marked enhancement of 
a variety of senescence-associated phenotypes that are already pres-
ent to a lesser degree in the untreated diabetic mice.
Methods
Animals. Mice were purchased from Jackson Laboratory and bred in our 
animal facility. Mice having the null allele for the bradykinin B2 receptor 
(Bdkrb2–/–) (58) were backcrossed to WT C57BL/6J at least 6 times before 
mating to mice heterozygous for the Akita mutation (Ins2Akita/+) (59), which 
already have the C57BL/6J genetic background. All experiments were 
approved by the University of North Carolina Institutional Animal Care 
and Use Committee. Bone mineral density in femurs was measured with 
dual-emission x-ray absorptiometry (LUNAR PIXImus 2; GE Healthcare) 
in the Body Composition Core of the Clinical Nutrition Research Center at 
the University of North Carolina. The histopathological data were obtained 
with tissues from at least 4 mice of each genotype. The specific images 
shown were selected as representative of the tissue from each genotype. 
The images illustrating the general appearance of the animals were of the 
severely affected mice of each of the genotypes. For assays where samples 
could be stored before processing, age-matched animals were euthanized 
at different times, but the assays themselves were performed together in 1 
batch. For quantitative measurements inherently sensitive to inadvertent 
experimental variations (for example, the assays for TBARSs), all samples 
were collected on the same day and measurements were made together.
8-OHdG levels and the frequency of point mutations in mtDNA. Mitochondrial 
DNA (mtDNA) was extracted from whole kidney using an mtDNA Extrac-
tor CT kit (Wako Pure Chemicals Industries Ltd.). The 8-OHdG levels in 
DNase I–digested mtDNA were determined by ELISA with a kit from the 
Japan Institute for the Control of Aging. To determine the sequence of the 
mitochondrial cytochrome b gene (GenBank accession number gi33115104) 
in our mtDNA samples, we amplified its coding region with Tgo DNA poly-
merase (Roche Applied Science) using primers shown in Supplemental Table 
1. The PCR-amplified fragments were subcloned into pBluescript II (Strata-
gene) and sequenced with M13 primers.
Quantification of mtDNA deletion mutants. Large deletions between 2 
homologous sequences in mtDNA have been reported in aged mice (31). 
We therefore assayed the most common deletion mutation, D-17, in our 
mtDNA samples using quantitative PCR with primers flanking the D-17 
deletion and with template mtDNAs cut at an MluI site present in the 
region deleted in D-17. The sequences of primers and probes for quantifi-
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cation of the normal and D-17–deleted cytochrome b gene are provided in 
Supplemental Table 2.
Quantitative RT-PCR. Total RNA was extracted from whole kidney, 
and the mRNAs for TGF-β1, CTGF, p53, FoxO1, and α-synuclein were 
assayed by quantitative RT-PCR. The sequences of the primers and 
probes for measurement of the expression of these genes are provided 
in Supplemental Table 3.
Measurement of TBARSs and GSH. The plasma levels of TBARSs were 
determined as described elsewhere (60). The concentration of reduced 
glutathione (GSH) in erythrocytes was measured with a Glutathione 
Assay kit (Calbiochem).
Microscopy. Fluorescence of MitoTracker Red CM-H2XRos (Invitrogen 
Corp.), an index of mitochondrial oxidation, was evaluated in EA.hy926 
vascular endothelial cells (33) with an IX70 inverted microscope (Olympus) 
equipped with a filter set for Texas red (exciter 560/55, dichroic 595, emitter 
645/75; Chroma Technology Corp.). In the NG medium, glucose was at 100 
mg/dl HBSS with Ca++ and Mg++ but without phenol red. Glucose was at 750 
mg/dl in the HG medium. BK, when used, was at 1 μM, and the NOS inhibi-
tor l-NAME was at 1 mM. The endothelial cells were incubated for 60 minutes 
in NG, HG, HG plus BK, or HG plus BK plus l-NAME medium before addi-
tion of MitoTracker Red CM-H2XRos (1 μM). Fluorescence was recorded 15 
minutes later with a SPOT RT Slider digital camera, and analyzed with SPOT 
version 4.0.9 (Diagnostic Instruments) and ImageJ 1.33u (NIH) software.
TUNEL assay. We performed TUNEL assay in the paraffin-embedded 
duodenum and testis using ApopTag Fluorescein In Situ Apoptosis Detec-
tion Kit (Chemicon International). A filter set for yellow fluorescent pro-
tein (exciter 500/20, dichroic 515, emitter 535/30; Chroma Technology 
Corp.) was used to detect the FITC fluorescence.
Statistics. Data are expressed as means ± SEM.	To compare the effects of 
diabetes, of absence of the B2 receptor, and of their combination, we used 
2-factor ANOVA with the program JMP 5.1.2 (SAS Institute Inc.; P values 
for 2-factor ANOVA are shown in Supplemental Table 4). Post hoc pair-
wise comparisons were by Tukey-Kramer HSD. P values less than 0.05 were 
considered significant.
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